Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:p>There is an increasing incidence and prevalence of MG in older patients (&gt;50 years) – defined as Late Onset Myasthenia Gravis (LOMG). This study aims to define the demographics, clinical features, response to treatment and immunological features which may distinguish LOMG from the early onset patients (who will also be recruited as controls).</jats:p><jats:p>Who to refer?</jats:p><jats:p>▸ All patients should be over the age of 18 years, able to provide informed consent.</jats:p><jats:p>▸ The study aims to recruit patients who are willing to travel to one of the myasthenia clinics in Birmingham, Nottingham or Oxford</jats:p><jats:p>▸ All patients with a new diagnosis of MG (or diagnosed in the last 12 months) prior to immunosuppression.</jats:p><jats:p>▸ Diagnosis of MG based on typical clinical features and the presence of AChR or MuSK Abs, or evidence of neuromuscular transmission defect on single fibre EMG.</jats:p><jats:p>What it involves for patients</jats:p><jats:p>▸ Management will be as per usual practice</jats:p><jats:p>▸ Annual serum samples at follow up with QoL and MG composite scores</jats:p><jats:p>▸ Follow up for 5 years (3 years by the clinical research fellow and 2 years optionally by the local participating neurologists).</jats:p>

Original publication




Conference paper



Publication Date





e4.49 - e4